While the influence of HLA-AB and -DRBI matching on the outcome of bone marrow transplantation (BMT) with unrelated donors is clear, the evaluation of HLA-C has been hampered by its poor serological definition. Because the low resolution of standard HLA-C typing could explain the significant number of positive cytotoxic T lymphocyte precursor frequency (CTLpf) tests found among HLA-AB-subtype, DRB I/B3/BS-subtype matched patient/donor pairs, we have identified by sequencing the incompatibilities recognized by CD8+ CTL clones obtained from such positive CTLpf tests. In most cases the target molecules were HLA-C antigens that had escaped detection by serology (e.g. Cw*1601, 1502 or 0702). Direct recognition of HLA-C by a CTL clone was demonstrated by lysis of the HLA class I-negative 721.22 1 cell line transfected with Cw* 160 1 cDNA. Because of the functional importance of Cw polymorphism, a PCR-SSO oligotyping procedure was set up allowing the resolution of 29 Cw alleles. Oligotyping of a panel of 382 individuals (including 101 patients and their 272 potential unrelated donors, 5 related donors and 4 platelet donors) allowed to determine HLA-C and HLA A-B-Cw-DRB I allelic frequencies, as well as a number of A-Cw, B-Cw, and DRB 1-Cw associations. Two new HLA-Cw alleles (Cw*02023 and Cw*0707) were identified by DNA sequencing of PCR-amplified exon 2-intron 2-exon 3 amplicons. Furthermore, we determined the degree of HLA-C compatibility in 287 matched pairs that could be formed from 73 patients and their 184 potential unrelated donors compatible for HLA-AB by serology and for HLA-DRBI/ B3/B5 by oligotyping. Cw mismatches were identified in 42.1% of these pairs, and AB-subtype oligotyping showed that 3oy0 of these Cw-incampatible pairs were also mismatched for A or B-locus subtype. The degree of HLA-C incompatibility was strongly influenced by the linkage with B alleles and by the ABDR haplotypes. Cw alkles linked with B*4403, B*5101, B i 8, and B62 haplotypes were frequently mismatched. Apparently high resolution DNA typing for HLA-AB does not result in full matching at locus C. Since HLA-C polymorpliism is recognized by alloreactive CTLs, such incompatibilities might be as relevant as AB-subtype mismatches in clinical transplantation.
HLA-C incompatibility in unrelated BNIT
The increased incidence of post-transplant complications after transplantation with bone marrow from an unrelated donor reflects the high frequency of HLA incompatibilities not resolved by standard tissue typing. Clinical studies have shown the influence of HLA-AB (serology) and -DRBl (DNA typing) matching on the outcome of BMT with unrelated donors. However, a thorough evaluation of HLA-C mismatches has not been possible yet because of the poor serological definition of HbA-C antigens, possibly due to the low level of cell surface expression (1, 2). HLA-C antigens are functional class I molecules that like HLA-A and B antigens are recognized by NK cells (3, 4) as w0lI as by CD8-positive T cells (5). Despite recent developments in PCR-based approaches for the analysis of HLA-C (69), very little information is currently available on the functional role of the diversity of locus C in BMT.
In our center, selection of unrelated bone marraw donors is based on AB serology, DRBl/ DRB3/DRBS oligotyping analysis (10, 11) and on a negative CTLpf assay (12) . We have studied in detail the mismatches recognized by the CTLs in order to develop comprehensive molecuiar typing methods that could eventually lead to a replacement of the CTLpf test.
In a previous analysis (13) , high resolution typing of HLA-ABDR I-14 matched donor/recipient pairs showed that only 28% of the donors were compatible on the basis of AB-subtype, DRB i/B3/ 85-oligo matching and CTLp-negativi ty. Common HLA class I subtype mismatches within A2, B35 or B44 (14, IS) serotypes were shown to cause the positive CTLpf tests (1 3). Furthermore, CTL clones derived from these combinations recognized the mismatched antigens, even when the sequence differences between the two alleles consisted of one or two amino acids onIy (16, 17) .
In this paper we present a sequencing anaIysis of HLA-C incompatibilities of three donor/recipient combinations with a positive CTLpf test that could not be accounted for by an A or B-subtype difference. In all three cases, HLA-C incompatibilities could be identified. Furthermore, direct recognition by the CTL clones of Cw mismatches was demonstrated by transfection of Cw* 160 1 cDNA into a class I-negative human cell line. In addition wc have developed a PCR-SSO oligotyping protocol in order to: a) determine the frequency of HLA-C alleles in our patient popuiation, b) to investigate the overall rate of HLA-C incompatibilities in AB-sero-DRB l/B3/BS-oligo matched pairs, and c) to analyze the co-occurrence of ACw, B-Cw, and DRB1-Cw antigens in the sampled phenotypes in order to propose ABDR haplotypes Lit risk to be mismatched for HLA-C.
Since HLA-C incompatibilities are recognized by CTLs, it is important to determine the extent of HLA-C incompatibility in the unrelated bone marrow transplantation setting. Knowledge of preferential HLA class I -class I1 associations, including linkage with HLA-Cw alleles, should therefore be helpful in focusing the pre-transplant molecular biology analyses on those haplotypes with highest probability to be incompatible.
Material and methods

Patients and donors
One hundred and one non-selected patients with blood disorders and their related (n=5) and unrelated (n=272) potential donors, as well as 4 platelet donors were typed by serology for HLA-AB (382 individuals in total) and by PCR/SSO-oligotyping for class 11. Subtypes of HLA-A2, 1335, B44, B7, B51 were determined by oligotyping as described elsewhere (14, 15, 18) . HLA-C polymorphism was determined by oligotyping as described below. DRBl/B3/B5 oligotyping was done by the microtiter plate oligotyping assay (bioMtrieux) detecting 60 alleles (1 9), and by dot blot SSO (20) and/or PCR-SSP (2 1) for high resolution DRB 1 typing. Calculation of HLA-C allelic and haplotype frequencies was done on the 101 patients and 4 platelet donors, and calculation of A/ C, B/C, C/DR associations was done on 382 individuals. For the evaluation of HLA matching we excluded 4 patients with a related donor (n=5) and the 4 platelet donors. From the remaining 97 patients and their 272 unrelated donors selected from international registries (369 individuals), 73 patients and their 184 donors were compatible for HLA-AB by serology and for DRB1/83/B5 by oli-. gotyping. This group formed 287 matched pairs that were used to calculate the rate of HLA-A/B and/or -Cw mismatching.
HLA-C amplification
Primers 5CZnl-61 and 3BCIn3-12 (22) were used to amplify the complete exon 2, intron 2 and exon 3 of HLA-C genes. Genomic DNA was prepared from granulocytes as previously described (14) . PCR reactions were performed in a total volume of 50 pl containing lxPCR buffer (Tris pH 8.8 10 mM, KCl 50 mM, MgCll 1.25 mM, BSA 0.2 cis/ ml), 0.5-1 pg of genomic DNA, 0.2 mM dNTPs, 0.25 pM each of the two primers, 1U Taq polymerase (Gibco BRL). After an initial denaturation step of 4 min at 94°C the cyciing conditions were as follow: 5 cycles with denaturation at 94°C for 30 s. annealing at 65°C for 50 s and extension at 72°C for 50 s followed by 25 cycles with denatura-tion at 94°C for 30 s, annealing at 63°C for 50 s and extension at 72°C for 50 s. Amplification efficiency was confirmed by agarose gel electrophoresis of 1/25 of the PCR product.
Hybridization with seq uence-specif ic oligonucleotide (SSO) probes
For high-resolution HLA-C oligotyping a total of 27 SSO probes were designed. The sequence, codon positions, and washing temperatures of all probes are given in Table 1 . Probes El63 (#9), G170 (#lo), A152-Ql56 (#14) and Pl05 (#22) are from Kennedy et a1 (9). The following HLA-C alleles were recently reported as being sequencing artifacts: Cw*0101, 1201, 1501 (23). Therefore the probes S178 (AGGAGAECTGCAG), V116 (CCAGGTCGCCTACG) and H 129 (TGAAC-GAGCACCTG) aimed at detecting these alleles and which always gave a negative signal, were dropped. Probe A152-Ql56 is only used to discriminate Cw*0704 from Cw*0701 in the presence of Cw"0602.
Two p1 of each PCR amplification was dot-blotted on a nylon membrane (Nytran, Schleicher & Schull) by a robotic workstation Biornek 1000. Table 1 . Sequence-specific exon 2 and 3 oligonucleotide probes far HLA-C typing The DNA was denatured by i 0 rnin in NaOW 0.4 M, neutralized by 10 min in NH4-acetate 1 M and cross-linked (optional) to the membrane by UV irradiation (120 mJ) with a Stratalinker (Stratagene). After blocking the membrane by 30 min incubation at 42°C with blocking solution (4xSSPE, 1"/0 blocking reagent (Boehringer Mannheim), 0.1% lauroylsarcosine) in a hybridization oven, the membranes were hybridized with 6 pmol of digoxigenin-labeled probes at 42°C for 2 h in TMAC buffer (3 M tetramethyl ammonium chloride (Fluka), 50 mM Tris-HC1, pH=8.0, 2 m M EDTA, 0.1% SDS). Washing was for 10 min in 2xSSPE -0.1% SDS followed by 15 min of stringent wash in TMAC buffer ( Table 1) . Detection of the DIG-labeIed probes by cherniluminescence, using CSPD as substrate, was done following the indications of the manufacturer (BoehringerMannheim).
Cloning and sequencing of exons 2 and 3 of HLA-C After HLA-C specific amplification of exon 2, intron 2 and exon 3 with primers 5CInl-61 and 3BCIn3-12 (22) , the PCR product was electrophoresed on a 1 %~ agarose gel, the band excised and purified with the Nucleotrdp kit (MachereyNagel) and ligated to the TA cloning vector ( h itrogen). After transformation the bacterial colonies were screened by PCR followed by SSO hybridization for the HLA-C allele of interest. Two ciones from two independent PGR were sequenced in both directions using Sequenase 2.0 (Amersham),
Cloning and stable transfection of HLA-CwV601
The mRNA was extracted from 1.106 cells (Fast Track, Pharmacia) and reverse transcribed by Superscript enzyme (Gibco BRL). 1/20 of the cDNA reaction was amplified with primers 5p2 and 3pC (24) in 1 XPCR buffer containing 1.5 mM MgC12. The initial denaturation step of 4 min at 94°C was fallawed by 30 cycles with denaturation at 94°C
for 60 s, annealing at 60°C for 60 s and extension at 72°C for 90 s. After gel purification and digestion with XhoVHindIII, the PCR product was subcloned in the pBJI-Neo vector (25) . The identity oif Cw*1601 was confirmed by sequencing. 20 pg of the plasmid was linearized by Xmnl and electroporated in the class I-negative cell line 721.22 1 (26). After selection with G418 a stable transfectant was isolated and the expression of Cw*1601 tested by FACS analysis using the anti-class I antibody W6/32. The transfected cell line was used in a conventional cytotoxici ty chromium release assay with the CTL clone as described (1 6, 17).
Gytotoxicity assays
CTLpf tests and specificity assays with cytotoxic T cell clones were performed as described ( 12, f 3, 16, 17), using autoIogous (donor) cells and third party cells that do not express HLA antigens in common as negative controls.
Frequency and linkage disequilibrium of HLA-C with other HLA loci HLA-C and DRBl allelic frequencies were estimated in 101 patients and 4 platelet donors of European origin living in Switzerland (total: 105 individuals) M aximum-likelihood allele and haplotype frequencies and their standard deviations were estimated by using the program package ARLE-QUIN (Schoeider S., Kueffer J.-M., Roessli D., and Excoffier L., personal communication). Gene frequencies were obtained starting with 10 initial values, and the iterative process was stopped when the epsilon value between the frequencies of two consecutive iterations was as low as The standard deviations were computed by a bootstrap procedure ( 100 bootstraps). Pairwise allelic associ- (Table 2) were analyzed by SSO-oligotyping for HLA-AB and by sequencing for HLA-C in order to identify class I incompatibilities undisclosed by serology. Table 2 shows that in all 3 cases the class I incompatibility mapped to locus HLA-C. In pairs 1 and 2, mismatched Cw alleles were Cw*160l (us 0401) and 1502 (vs 1601), respectively, both of which had been typed as serological blanks. In pair 3, the incompatible allele was a subtype of Cw7 (Cw*0702 vs 0501). Analysis of the CTL specificity on a panel of HLA-A,B,C,DR well characterized cells showed that these HLA-C incompatibilities were indeed the targets recognized (data not shown). Two CTL clones established in pair I recognized 16 of 27 B*4403-Cw serologically blank panel cells so that it became likely that these CTL were directed against the Cw blank antigen (16) . After identification of the Cw*1601 allele in the patient of this pair 1, we typed the 27 cells from the panel used for the CTL specificity test by hybridization with probe Q 156 which is Cw* 160 1/1602-specific. We found that all 16 target cells lysed by the CTLs were Ql56-positive, whereas 10 of 1 I cells that were not lysed were Q156-negative. To study this in more detail, we sequenced the HLA-C of the Q 156-positive cell (AY3 B5 1/7 Cw7/blank) that was not Iysed by the CTL clones and found that it corresponded to Cw* 1602. allele (28) that differs from 1601 at 2 residues (positions 77 and 80).
Similarly, the specificity of a CTL clone derived (Figure 1) we concluded that the Cw*1601 antigen was recognized directly.
HLA-C oligotyping analysis of patients an# their unrelated bone marrow donors: HLA-C allelic ftequencies and linkage disequilibrium with other HLA loci
Because of the functional importance of the HLA-C incompatibilities, we set up a PCR-SSO oligotyping procedure with locus C-specific primers (22) and a total of 27 SSO probes (Table 1) Table  3 . As the A, B, and DRBl frequencies in the patients' group are close to the frequencies previously determined in a local panel of 151 platelet donors (271, the HLA-C allelic frequencies in the patients' group should also be representative of the Swiss population. No bias seems to be introduced, either by the diseases, or by the fact that onty patients for whom serologically identica1 donors could be selected from the bone marrow donor registries were analyzed. Cw*0401, 0702, 0701, and 0501 are the most frequent alleles, reflecting the high frequency of the (linked) B35, 97, B8, and B44 antigens in Etiropeans. The heterozygosity level of locus C is 0.909. which is very close to the heterozygosity levels previously crilcuiated for HLA-B (0.926) and DRBl (0.923) loci (27) . This result contrasts with the very low level of Cw diversity previously detected by serology, and suggests that this locus may be subject to heterozygous advantage, as it is often shown for other HLA loci. However, the homozygosity observed in the Swiss sample (Fob,=O.09l) here falls within the limits of a 95% confidence interval for the homozygosity expected under neutrality (F,,, 
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Full exon 3, intron 2, and exon 3 nucleotide sequence of Cw*02023 (EMBL accession number 272007) from cell KACD. For comparison the exons 2 + 3 sequences of Cw*OZOZ1 and 02022 are indicated (34). The name Cw*02033 hus been officidty assigned by the WHO Nomenclature Committee in May 1996. This follows the iigreed policy that, subject to the conditions stated in the most recent nomenclature report (35) . names will be ussignrd to new sequences ;ts they are identified. Lists of such new names will be published in the Vollowing WHO nomenc1;rtiire report. Ocilober 1996, This follows the agreed policy that subject to the conditions stated in the most recent nomenclature report ( 3 9 , natrics will be assigned to new sequences as they are identified. A list of such new iiarnes will be published in the following WHO norwmhiture report.
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equilibrium with Cw*0701, as well as the intron 2 sequence comparison (Figure 3 ) (36), support the hypothesis that Cw*0707 resulted from a gene conversion-like event that involved transfer of ii short segment of the alpha I domain comprising at least codons 77-90 in a Cw*0701 recipient allele. The boundaries of this putative recombination would be situated within codons 44-76 at the 5'-end de-pending on the donor allele, and between nucleotides 1-80 of intron 2 at the 3'-end. Interestingly, the CTLpf test performed in the intra-Familial combination that differed only at the locus HLA-C (Cw*0707 versus Cw*0701) was positive (3 precursors/106). This implies that the motif S77-N80-D90 on the a-helix is important for CTL allorecogni tion.
Frequency of mismatched HLA-C alleles in AB-sero-and DRB1/B3/BS-oligo-compatible pairs
We have previously shown that high-resolution DRB 1/B3/B5 matching significantly affects the rate of HLA-A and -B subtype compatibility (1 5). Linkage disequilibria will also determine the rate of HLA-C incompatibilities in combinations matched for ABDR antigens. We assessed the chance of being mismatched for HLA-C by studying the 287 matched pairs that could be formed from 73 patients and their 184 potential unrelated donors compatible for HLA-AB by serology and for DRBl/B3/BS by oligotyping. In all of these pairs AB-subtype and HLA-C polymorphism were determined by oligotyping and/or sequencing. As shown in Figure 4 , the overall degree of ABC match was 51.3%. That is, even after high resolution DRB matching, about half of the potential donors will still be incompatible for at least one CIass I antigen. 24.6% of the pairs were incompatible for HLA-C only, whereas 12.50/0 were mismatched for HLA-A/B and HLA-C and 6.6% for HLA-A/B only. It should be noted that of the 44 patient/donor combinations that were incompatible for HLA-C, 41 were CTLp-positive. All of the 17 pairs that had an additional A or €3 mismatch as determined by oligotyping were in the group with a positive CTLp test. In the 27 pairs, in which the absence of The results shown in Tables 3 and 4 suggest that certain ABDR haplotypes are at relatively tow risk to be mismatched for HLA-C. The common haplotypes A1 -B8-Cw*070 1-DRB 1 *0301 -DRB3*0101, A*030l -B*0702-Cw*0702-DRBl* 1501, or Ax-B*4402-Cw*O501-DRBl*04/1301/1501 can thus be considered as "low risk haplotypes" with respect to Cw incompatibility. In contrast, Cw mismatches occur frequently in haplotypes containing the B*4403, B*5101, B18, or 862, alleles ( 
Discussion
The data presented here illustrate the relevance of HLA-C incompatibilities for the matching of unrelated donorlrecipient combinations. Firstly, they show that CTLs recognize HLA-C incompatibiIities almost as efficiently as they recognize HLA-A or HLA-B incompatibilities. In all but 3 of the 27 tested combinations with a Cw mismatch only, the Cw incompatibility resulted in a positive CTLp test. Of the three HLA-C incompatible pairs with a negative CTLp test, in one combination the misrrbatched alleles were Cw*0303 versus Cw*0304, which differ for a single amino acid (position 91) outside the peptide binding groove. One might argue that such differences are immunologically irrelevant (37) and therefore, could be considered as an acceptable mismatch. The other two cornbin,a tions however, were common HLA-mismatches (Cw* 1502 versus 170 1, Cw*0304 versus 050 1) which should have induced an ailogenic reaction. We are reluctant to speculate on these two cases, in particular because we could not repeat the CTLp tests due to lack of viable patient cells.
The second finding of this report is that, even in well matched donodrecipient combinations HLA-C mismatches are rather frequent. A large scale analysis of donodrecipient pairs was done with an aligotyping protocol based on hybridization with 27 SSO probes following one locus C-specific exclns 2 + 3 PCR. This oligotyping procedure covered practically all of the sequenced C w alleles and has qow been introduced in our routine typing laboratory. It is highly efficient to pick-up new alleles by identifying new hybridization patterns, which allowed us to detect 2 new Cw alleles, Cw*02023 and Cw*0707. The analysis of 287 pairs of HLA AB-serology, DRB lIB3IBS-oligo matched patients and unrelated donors revealed an overall HLA-C qisrnatching rate of 42.1%. In 30% of these cases the Cw incompatibility was accompanied by a subtype-mismatch at either one or both HLA-A and E$ loci, as determined by SSO-oligatyping for A?, ~4 3~ B7, B41, B44, or B5 1, or by sequencing analystis. This rate of HLA-C mismatch is comparable (3840) or higher (7) to those observed previously cbn a significantly lower number of pairs. The identification of "high-risk haplotypes" (e.g. B44, 85 1) with respect to Cw incompatibility iinderline t h e idvantage of H LA-Cw DNA typing for the optimal selection of HLA class I-matched donors.
A strong correlation between high CTLp frequencies and incompatibilities at locus HLA-C has recently been reported (39). Because of the variable linkage disequilibria between B and C alleles, the effect of individual C mismatches on cellular reactivity is difficult to evaluate without high resolution A/B typing. It is interesting to note that 8 of the 9 Cw-mismatched combinations in this study (39) are linked to either B14, B44 or BYB51, three antigens known to be split into subtypes. The high CTLpf values reported by these authors in 8 of the 9 combinations could therefore also be accounted for by a B+Cw mismatch (eg. typically B*4402-Cw*0501 versus B*4403-Cw*I601).
Differences in the clinical outcome for patients with serologically distinguishable ("major") HLA-AB mismatches or with ("minor") mismatches of HLA-AB antigens that share serologically defined epitopes (41) could be partially explained by the presence of additional Cw incompatibilities that are frequently associated with the major serological AB incompatibilities. As a consequence, sero--logically A13 mismatched donodrecipien t pairs will more often be mismatched for a second (HLA-C) antigen, possibly increasing the risk of post transplant complications. On the other hand, depending of the HLA-B-subtype mismatch, additional Cw incompatibility may also occur more frequently, as was observed in the case of B"4402 versus B*4403. Such pairs, that would have been classified in a group with "minor" HLA incompatibilities, are in fact mismatched at both HLA-B and -C loci.
The impact on patient's survival of HLA class I mismatches identified by serology (42) (43) (44) , by the CTLpf test (12, 45) , or by a Combination of serology/DNA typing and CTLp analysis (46) has been reported. in the present study we have shown that, although the frequencies in the CTLpf test might be lower, HLA-C incompatibilities are recognized by alloreactive CTLs. Clinical consequences of a single HLA-C incompatibility can now be analyzed. Our clinical data are still preliminary, because unti! now we could study only ten patients transplanted with an HLA-AB subtype, DRB 1/B3/ BS-oligo-matched but Cw-mismatched unrelated donor. Of these patients 40% are alive (follow-tip: 0.5 to 6.5 years) which is in between the 3-year survival probability of our group of patients with a HLA-ABCDRB l/B3/BS/DQB 1-matchedCTLpf-negative unrelated donor and that of a mismatched group (46). The predictive value of a positive CTLp test for increased risk of GvHD and decreased survival (1 2, 45) suggests that, whenever possible, we should consider Cw incompatibilities in the donor selection procedure. Such incompati-bilities which have now become easy to detect by PCR-SSO hybridization or by PCR-SSP might be as relevant as AB-subtype mismatches in clinical transplantation.
